The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant prostate cancer (mCRPC) therapy session and a presentation by Dr ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

The Bellmunt Risk Score can provide prognostic information on survival among patients with metastatic castration-resistant prostate cancer, new data suggest.

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced prostate cancer, according to a phase II clinical trial conducted at Kurume ...

In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.

Using de-identified data from the National Cancer Institute, researchers followed 205 patients—average age, 61 years—with prostate cancer and preexisting depression. Patients with both conditions had ...

Add Yahoo as a preferred source to see more of our stories on Google. If a person has an "aggressive" prostate cancer with a Gleason score of 9, what does that mean? What's the outlook when it comes ...

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...